Drug Profile


Alternative Names: Anti-CD45 monoclonal antibody; Leucocyte modulator CD45

Latest Information Update: 17 Apr 1997

Price : $50

At a glance

  • Originator Xenova Group
  • Developer Baxter Healthcare Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD45 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Renal transplant rejection

Most Recent Events

  • 17 Apr 1997 Discontinued-Unspecified for Diabetes mellitus in United Kingdom (Unknown route)
  • 19 Apr 1996 Discontinued-II for Renal transplant rejection in United Kingdom (Unknown route)
  • 19 Apr 1996 Discontinued-Unspecified for Renal transplant rejection in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top